Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...
Source: europapress.es